Finding the best dose of anti-lymphocyte globulin for kidney transplant patients
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial is testing different doses of a drug called anti-lymphocyte globulin (which helps prevent the body from rejecting a new kidney) to find the best one for people who are getting their first kidney transplant and have a low risk of rejection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are getting your first kidney transplant.
- You are not at high risk for rejecting the new kidney (your doctor will check this).
- If you are a woman who can have children, you must use effective birth control and have a negative pregnancy test before the study starts.
- If you are a man with a partner who can have children, you must use barrier contraception during the study and for 6 months after stopping the study drug.
- You are covered by French social security and can give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses DNA testing and gene expression profiling to see if kidney transplant recipients can safely switch to a belatacept-only immunosuppression regimen. The goal is to simplify your anti-rejection drugs while keeping your kidney healthy.
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
This trial tests whether giving albumin (a protein in your blood) after a liver transplant can help prevent or reduce kidney damage. It is for adults receiving their first liver-only transplant from a deceased donor.
This study tests whether a special blood test can help monitor your new kidney after transplant. It may help doctors spot problems earlier and improve kidney health.
This trial tests a blood test that may help monitor kidney transplant health by detecting signs of rejection earlier. It aims to see if using this blood test can lead to better long-term outcomes for transplant recipients.
This trial tests whether switching from a standard anti-rejection medicine to a different one (everolimus) about a year after a liver transplant can help protect your new liver with fewer side effects. If you qualify, you will be monitored closely for a few years to see how well the new medicine works for you.
Hear when a new Renal Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.